Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion

Brian T. Kim, Stephen G. Schwartz, William E. Smiddy, Rishi R. Doshi, Jaclyn L. Kovach, Audina M. Berrocal, Andrew A. Moshfeghi, Jorge A. Fortun

Research output: Contribution to journalReview article

53 Scopus citations

Abstract

BACKGROUND AND OBJECTIVE: When delivered via a single intravitreal injection, ocriplasmin can effect proteolytic resolution of symptomatic vitreomacular adhesion (VMA). The authors describe their initial clinical experience with ocriplasmin at a large academic center. PATIENTS AND METHODS: Retrospective review of all patients with symptomatic VMA treated with ocriplasmin from January 2013 through May 2013 at a single center. RESULTS: Nineteen patients with symptomatic VMA received intravitreal ocriplasmin. Eight patients (42%) exhibited resolution of VMA. Macular holes in three of six patients (50%) closed after injection. A higher proportion of VMA resolution was observed in patients with the following baseline characteristics: age less than 65 years, focal adhesions less than or equal to 1,500 μm, presence of macular hole, phakic status, and absence of epiretinal membrane. CONCLUSION: Initial clinical outcomes using ocriplasmin in this study are consistent with those reported in the phase 3 clinical trials. Improved clinical results can be achieved with careful case selection based on specific baseline characteristics.

Original languageEnglish (US)
Pages (from-to)334-343
Number of pages10
JournalOphthalmic Surgery Lasers and Imaging Retina
Volume44
Issue number4
DOIs
StatePublished - Jan 1 2013

    Fingerprint

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology

Cite this